Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan

March 18, 2019
Pharmaceutical Technology Editors

The expansion includes a new R&D laboratory and the installation of a 12,000-liter reactor at one of the company’s manufacturing facilities on its Paullo site in Milan, Italy.

Cambrex, a small-molecule company providing drug substance, drug product, and analytical services across the drug lifecycle, announced on March 14, 2019 that it has completed the expansion of a new 150-mR&D laboratory at its site in Paullo, Milan, Italy.

The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass-lined reactors as well as analytical instruments, including multiple high- and ultra-performance liquid chromatography, as well as gas chromatography systems, which have now been qualified and validated, the company reports. To complement investments at other Cambrex sites, the new laboratory has also installed a flow chemistry system to allow for continuous manufacturing development.

Additionally, the company has installed a new 12,000-liter reactor into one of its cGMP manufacturing facilities at the site. The installation of the reactor, along with the replacement of centrifuges with new equipment in one of the site’s seven production departments, is part of a $3-million investment to upgrade and improve the efficiency of the plant, which manufactures intermediates and generic APIs under GMP conditions.

“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” said Aldo Magnini, managing director, Cambrex Milan, in a company press release. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”

Source: Cambrex